CN103156930A - 一种含芍药和甘草提取物的呼吸道给药制剂 - Google Patents
一种含芍药和甘草提取物的呼吸道给药制剂 Download PDFInfo
- Publication number
- CN103156930A CN103156930A CN2011104303673A CN201110430367A CN103156930A CN 103156930 A CN103156930 A CN 103156930A CN 2011104303673 A CN2011104303673 A CN 2011104303673A CN 201110430367 A CN201110430367 A CN 201110430367A CN 103156930 A CN103156930 A CN 103156930A
- Authority
- CN
- China
- Prior art keywords
- radix
- extract
- licorice
- respiratory tract
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000284 extract Substances 0.000 title claims abstract description 47
- 238000002360 preparation method Methods 0.000 title claims abstract description 32
- 210000002345 respiratory system Anatomy 0.000 title claims abstract description 28
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 title claims abstract description 14
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 title claims abstract description 14
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 title claims abstract description 14
- 229940010454 licorice Drugs 0.000 title claims abstract description 14
- 240000004670 Glycyrrhiza echinata Species 0.000 title 1
- 244000236658 Paeonia lactiflora Species 0.000 title 1
- 235000008598 Paeonia lactiflora Nutrition 0.000 title 1
- 206010011224 Cough Diseases 0.000 claims abstract description 20
- 208000006673 asthma Diseases 0.000 claims abstract description 17
- 241000202807 Glycyrrhiza Species 0.000 claims abstract description 14
- 235000006484 Paeonia officinalis Nutrition 0.000 claims abstract description 13
- 239000000443 aerosol Substances 0.000 claims abstract description 13
- 239000007921 spray Substances 0.000 claims abstract description 13
- 241000736199 Paeonia Species 0.000 claims abstract description 9
- 239000003380 propellant Substances 0.000 claims abstract description 8
- 239000000796 flavoring agent Substances 0.000 claims abstract description 7
- 239000000843 powder Substances 0.000 claims abstract description 7
- 235000013355 food flavoring agent Nutrition 0.000 claims abstract description 5
- 239000004615 ingredient Substances 0.000 claims abstract description 5
- 239000003381 stabilizer Substances 0.000 claims abstract description 4
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims abstract description 3
- 238000007796 conventional method Methods 0.000 claims abstract description 3
- 239000003085 diluting agent Substances 0.000 claims abstract description 3
- 239000004094 surface-active agent Substances 0.000 claims abstract description 3
- 230000000241 respiratory effect Effects 0.000 claims abstract 3
- 239000000203 mixture Substances 0.000 claims description 15
- VYQNWZOUAUKGHI-UHFFFAOYSA-N monobenzone Chemical compound C1=CC(O)=CC=C1OCC1=CC=CC=C1 VYQNWZOUAUKGHI-UHFFFAOYSA-N 0.000 claims description 15
- YKRGDOXKVOZESV-WRJNSLSBSA-N Paeoniflorin Chemical compound C([C@]12[C@H]3O[C@]4(O)C[C@](O3)([C@]1(C[C@@H]42)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)C)OC(=O)C1=CC=CC=C1 YKRGDOXKVOZESV-WRJNSLSBSA-N 0.000 claims description 11
- 238000009472 formulation Methods 0.000 claims description 10
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 claims description 9
- 229960004949 glycyrrhizic acid Drugs 0.000 claims description 9
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 claims description 9
- 235000019410 glycyrrhizin Nutrition 0.000 claims description 9
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 claims description 9
- MPDGHEJMBKOTSU-YKLVYJNSSA-N 18beta-glycyrrhetic acid Chemical compound C([C@H]1C2=CC(=O)[C@H]34)[C@@](C)(C(O)=O)CC[C@]1(C)CC[C@@]2(C)[C@]4(C)CC[C@@H]1[C@]3(C)CC[C@H](O)C1(C)C MPDGHEJMBKOTSU-YKLVYJNSSA-N 0.000 claims description 8
- VTAJIXDZFCRWBR-UHFFFAOYSA-N Licoricesaponin B2 Natural products C1C(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2)C(O)=O)C)(C)CC2)(C)C2C(C)(C)CC1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O VTAJIXDZFCRWBR-UHFFFAOYSA-N 0.000 claims description 8
- 229930182478 glucoside Natural products 0.000 claims description 8
- 239000001685 glycyrrhizic acid Substances 0.000 claims description 8
- MPDGHEJMBKOTSU-UHFFFAOYSA-N Glycyrrhetinsaeure Natural products C12C(=O)C=C3C4CC(C)(C(O)=O)CCC4(C)CCC3(C)C1(C)CCC1C2(C)CCC(O)C1(C)C MPDGHEJMBKOTSU-UHFFFAOYSA-N 0.000 claims description 6
- 229960003720 enoxolone Drugs 0.000 claims description 6
- 150000008131 glucosides Chemical class 0.000 claims description 6
- 150000007949 saponins Chemical class 0.000 claims description 6
- -1 ester glycosides Chemical class 0.000 claims description 4
- 229930182490 saponin Natural products 0.000 claims description 4
- 235000017709 saponins Nutrition 0.000 claims description 4
- 239000002552 dosage form Substances 0.000 claims description 3
- 229930182470 glycoside Natural products 0.000 claims description 2
- YKRGDOXKVOZESV-UHFFFAOYSA-N paeoniflorin Natural products O1C(C)(C2(CC34)OC5C(C(O)C(O)C(CO)O5)O)CC3(O)OC1C24COC(=O)C1=CC=CC=C1 YKRGDOXKVOZESV-UHFFFAOYSA-N 0.000 claims 2
- 239000004378 Glycyrrhizin Substances 0.000 claims 1
- 229930003935 flavonoid Natural products 0.000 claims 1
- 235000017173 flavonoids Nutrition 0.000 claims 1
- 150000002215 flavonoids Chemical class 0.000 claims 1
- LTINPJMVDKPJJI-UHFFFAOYSA-N iodinated glycerol Chemical compound CC(I)C1OCC(CO)O1 LTINPJMVDKPJJI-UHFFFAOYSA-N 0.000 claims 1
- 229940069445 licorice extract Drugs 0.000 claims 1
- 239000003595 mist Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 abstract description 30
- 229940079593 drug Drugs 0.000 abstract description 14
- 230000000694 effects Effects 0.000 abstract description 12
- 238000005507 spraying Methods 0.000 abstract description 5
- 230000008685 targeting Effects 0.000 abstract description 3
- 239000000463 material Substances 0.000 abstract description 2
- 238000012377 drug delivery Methods 0.000 abstract 1
- 230000003902 lesion Effects 0.000 abstract 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 20
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 12
- 241000700199 Cavia porcellus Species 0.000 description 11
- 238000000034 method Methods 0.000 description 9
- 229910021529 ammonia Inorganic materials 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 230000003110 anti-inflammatory effect Effects 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- WNIFXKPDILJURQ-UHFFFAOYSA-N stearyl glycyrrhizinate Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C)CCC(C(=O)OCCCCCCCCCCCCCCCCCC)(C)CC5C4=CC(=O)C3C21C WNIFXKPDILJURQ-UHFFFAOYSA-N 0.000 description 4
- 238000005303 weighing Methods 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 230000002496 gastric effect Effects 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 238000012856 packing Methods 0.000 description 3
- 239000000825 pharmaceutical preparation Substances 0.000 description 3
- 229940098458 powder spray Drugs 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 239000011347 resin Substances 0.000 description 3
- 229920005989 resin Polymers 0.000 description 3
- 210000002460 smooth muscle Anatomy 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- 206010010904 Convulsion Diseases 0.000 description 2
- DEMKZLAVQYISIA-UHFFFAOYSA-N Liquirtin Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C(C2OC3=CC(O)=CC=C3C(=O)C2)C=C1 DEMKZLAVQYISIA-UHFFFAOYSA-N 0.000 description 2
- 208000007101 Muscle Cramp Diseases 0.000 description 2
- 244000170916 Paeonia officinalis Species 0.000 description 2
- 241001106477 Paeoniaceae Species 0.000 description 2
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 description 2
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 208000005392 Spasm Diseases 0.000 description 2
- 208000025865 Ulcer Diseases 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 230000008602 contraction Effects 0.000 description 2
- 230000036461 convulsion Effects 0.000 description 2
- 239000003480 eluent Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 238000011049 filling Methods 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 238000007670 refining Methods 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 208000023504 respiratory system disease Diseases 0.000 description 2
- 229910052709 silver Inorganic materials 0.000 description 2
- 239000004332 silver Substances 0.000 description 2
- 231100000397 ulcer Toxicity 0.000 description 2
- LVGUZGTVOIAKKC-UHFFFAOYSA-N 1,1,1,2-tetrafluoroethane Chemical compound FCC(F)(F)F LVGUZGTVOIAKKC-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- LATYEZNGPQKAIK-UHFFFAOYSA-N 6'-O-benzoylpaeoniflorin Natural products O1C(C)(C2(CC34)OC5C(C(O)C(O)C(COC(=O)C=6C=CC=CC=6)O5)O)CC3(O)OC1C24COC(=O)C1=CC=CC=C1 LATYEZNGPQKAIK-UHFFFAOYSA-N 0.000 description 1
- 206010000087 Abdominal pain upper Diseases 0.000 description 1
- 206010003591 Ataxia Diseases 0.000 description 1
- 208000008035 Back Pain Diseases 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- LATYEZNGPQKAIK-HRCYFWENSA-N Benzoylpaeoniflorin Chemical compound C([C@]12[C@H]3O[C@]4(O)C[C@](O3)([C@]1(C[C@@H]42)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](COC(=O)C=2C=CC=CC=2)O1)O)C)OC(=O)C1=CC=CC=C1 LATYEZNGPQKAIK-HRCYFWENSA-N 0.000 description 1
- 206010006458 Bronchitis chronic Diseases 0.000 description 1
- 206010010947 Coordination abnormal Diseases 0.000 description 1
- MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 description 1
- 208000015220 Febrile disease Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 208000008930 Low Back Pain Diseases 0.000 description 1
- 208000006735 Periostitis Diseases 0.000 description 1
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 description 1
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 description 1
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 210000003489 abdominal muscle Anatomy 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000000274 adsorptive effect Effects 0.000 description 1
- NDAUXUAQIAJITI-UHFFFAOYSA-N albuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-UHFFFAOYSA-N 0.000 description 1
- VIWQCBZFJFSCLC-UHFFFAOYSA-N alpha-benzoyloxypaeoniflorin Natural products O1C(C)(C2(CC34)OC5C(C(O)C(O)C(COC(=O)C=6C=CC=CC=6)O5)O)CC3(O)OC1C24COC(=O)C1=CC=C(O)C=C1 VIWQCBZFJFSCLC-UHFFFAOYSA-N 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 230000000954 anitussive effect Effects 0.000 description 1
- 230000000146 antalgic effect Effects 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000000767 anti-ulcer Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 238000000889 atomisation Methods 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000000812 cholinergic antagonist Substances 0.000 description 1
- 208000007451 chronic bronchitis Diseases 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 229930003944 flavone Natural products 0.000 description 1
- 150000002213 flavones Chemical class 0.000 description 1
- 235000011949 flavones Nutrition 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 239000008563 guizhi decoction Substances 0.000 description 1
- UKACHOXRXFQJFN-UHFFFAOYSA-N heptafluoropropane Chemical compound FC(F)C(F)(F)C(F)(F)F UKACHOXRXFQJFN-UHFFFAOYSA-N 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- 150000005828 hydrofluoroalkanes Chemical class 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 208000016290 incoordination Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 208000002551 irritable bowel syndrome Diseases 0.000 description 1
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- QYSGYZVSCZSLHT-UHFFFAOYSA-N octafluoropropane Chemical compound FC(F)(F)C(F)(F)C(F)(F)F QYSGYZVSCZSLHT-UHFFFAOYSA-N 0.000 description 1
- JLFNLZLINWHATN-UHFFFAOYSA-N pentaethylene glycol Chemical compound OCCOCCOCCOCCOCCO JLFNLZLINWHATN-UHFFFAOYSA-N 0.000 description 1
- 229960004065 perflutren Drugs 0.000 description 1
- 210000003460 periosteum Anatomy 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 229960001285 quercetin Drugs 0.000 description 1
- 235000005875 quercetin Nutrition 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000004064 recycling Methods 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 229960002052 salbutamol Drugs 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 230000002048 spasmolytic effect Effects 0.000 description 1
- 235000013599 spices Nutrition 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 206010044652 trigeminal neuralgia Diseases 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 241000712461 unidentified influenza virus Species 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims (5)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2011104303673A CN103156930A (zh) | 2011-12-19 | 2011-12-19 | 一种含芍药和甘草提取物的呼吸道给药制剂 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2011104303673A CN103156930A (zh) | 2011-12-19 | 2011-12-19 | 一种含芍药和甘草提取物的呼吸道给药制剂 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN103156930A true CN103156930A (zh) | 2013-06-19 |
Family
ID=48580795
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2011104303673A Pending CN103156930A (zh) | 2011-12-19 | 2011-12-19 | 一种含芍药和甘草提取物的呼吸道给药制剂 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103156930A (zh) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20180132143A (ko) * | 2016-04-15 | 2018-12-11 | 치아타이 티안큉 파마수티컬 그룹 주식회사 | 이소글리시리진산 또는 이의 염의 흡입용 제제, 및 호흡 기관 질환을 치료하기 위한 약물의 제조에서의 용도 |
| CN112190706A (zh) * | 2020-09-29 | 2021-01-08 | 新疆前进荣耀投资有限公司 | 乌拉尔甘草醇提取物在制备治疗自身免疫性疾病的免疫耐受佐剂中的应用 |
| CN114259523A (zh) * | 2020-09-16 | 2022-04-01 | 四川省中医药科学院 | 一种中药组合物及其在制备治疗咳嗽变异性哮喘的药物中的用途 |
| CN115844906A (zh) * | 2022-09-23 | 2023-03-28 | 复旦大学附属华山医院 | 芍药内酯苷在制备治疗气道炎症性疾病的药物中的应用 |
| WO2023146294A1 (ko) * | 2022-01-28 | 2023-08-03 | 경북대학교 산학협력단 | 작약 추출물을 포함하는 만성폐쇄성폐질환 예방 또는 치료용 약학적 조성물 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1519002A (zh) * | 2003-01-20 | 2004-08-11 | 四川省中药研究所 | 一种中药提取物及制备方法和应用 |
-
2011
- 2011-12-19 CN CN2011104303673A patent/CN103156930A/zh active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1519002A (zh) * | 2003-01-20 | 2004-08-11 | 四川省中药研究所 | 一种中药提取物及制备方法和应用 |
Non-Patent Citations (1)
| Title |
|---|
| 李富生等: "芍药甘草散治疗哮喘", 《中医杂志》 * |
Cited By (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11534398B2 (en) | 2016-04-15 | 2022-12-27 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Inhaled preparation of isoglycyrrhizic acid or salt thereof, and use in preparing drugs for treating respiratory system diseases |
| JP2019511556A (ja) * | 2016-04-15 | 2019-04-25 | チア タイ ティエンチン ファーマシューティカル グループ カンパニー リミテッドChia Tai Tianqing Pharmaceutical Group Co., Ltd. | イソグリチルリチン酸またはその塩の吸入製剤および呼吸器疾患を治療する薬物の製造におけるそれらの応用 |
| EP3443954A4 (en) * | 2016-04-15 | 2019-11-20 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | INHALED PREPARATION OF ISOGLYCYRRIC ACID OR SALT AND USE IN THE PRODUCTION OF MEDICAMENTS FOR THE TREATMENT OF RESPIRATORY DISEASES |
| JP7309791B2 (ja) | 2016-04-15 | 2023-07-18 | チア タイ ティエンチン ファーマシューティカル グループ カンパニー リミテッド | イソグリチルリチン酸またはその塩の吸入製剤および呼吸器疾患を治療する薬物の製造におけるそれらの使用 |
| JP2021176903A (ja) * | 2016-04-15 | 2021-11-11 | チア タイ ティエンチン ファーマシューティカル グループ カンパニー リミテッドChia Tai Tianqing Pharmaceutical Group Co., Ltd. | イソグリチルリチン酸またはその塩の吸入製剤および呼吸器疾患を治療する薬物の製造におけるそれらの応用 |
| AU2017251548B2 (en) * | 2016-04-15 | 2022-02-17 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Inhaled preparation of isoglycyrrhizic acid or salt thereof and use in preparing drugs for treating respiratory system diseases |
| KR20180132143A (ko) * | 2016-04-15 | 2018-12-11 | 치아타이 티안큉 파마수티컬 그룹 주식회사 | 이소글리시리진산 또는 이의 염의 흡입용 제제, 및 호흡 기관 질환을 치료하기 위한 약물의 제조에서의 용도 |
| KR102410183B1 (ko) * | 2016-04-15 | 2022-06-17 | 치아타이 티안큉 파마수티컬 그룹 주식회사 | 이소글리시리진산 또는 이의 염의 흡입용 제제, 및 호흡 기관 질환을 치료하기 위한 약물의 제조에서의 용도 |
| JP7166929B2 (ja) | 2016-04-15 | 2022-11-08 | チア タイ ティエンチン ファーマシューティカル グループ カンパニー リミテッド | イソグリチルリチン酸またはその塩の吸入製剤および呼吸器疾患を治療する薬物の製造におけるそれらの使用 |
| CN114259523A (zh) * | 2020-09-16 | 2022-04-01 | 四川省中医药科学院 | 一种中药组合物及其在制备治疗咳嗽变异性哮喘的药物中的用途 |
| CN112190706A (zh) * | 2020-09-29 | 2021-01-08 | 新疆前进荣耀投资有限公司 | 乌拉尔甘草醇提取物在制备治疗自身免疫性疾病的免疫耐受佐剂中的应用 |
| CN112190706B (zh) * | 2020-09-29 | 2024-02-09 | 新疆前进荣耀投资有限公司 | 乌拉尔甘草醇提取物在制备治疗自身免疫性疾病的免疫耐受佐剂中的应用 |
| WO2023146294A1 (ko) * | 2022-01-28 | 2023-08-03 | 경북대학교 산학협력단 | 작약 추출물을 포함하는 만성폐쇄성폐질환 예방 또는 치료용 약학적 조성물 |
| CN115844906A (zh) * | 2022-09-23 | 2023-03-28 | 复旦大学附属华山医院 | 芍药内酯苷在制备治疗气道炎症性疾病的药物中的应用 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101524524A (zh) | 一种治疗重症感冒的药物及其制备方法 | |
| CN101239081A (zh) | 一种用于癌症治疗的组合物及其制备方法 | |
| CN102319294B (zh) | 双香草制剂及其制备方法 | |
| CN103156930A (zh) | 一种含芍药和甘草提取物的呼吸道给药制剂 | |
| CN102258742A (zh) | 一种治疗抑郁症的中药组合物及其制备方法 | |
| CN104436145B (zh) | 一种预防和/或治疗过敏性鼻炎及过敏性哮喘的药物组合物 | |
| CN102357181B (zh) | 一种治疗咳嗽的中药组合物及其制备方法 | |
| CN100475263C (zh) | 治疗慢性阻塞性肺病的药物及其制备方法 | |
| CN1073439C (zh) | 一种治疗气管炎、哮喘病的药物及制备方法 | |
| CN104840737B (zh) | 具有补气润肺作用的中药组合物及其制备方法和应用 | |
| CN106266871A (zh) | 一种用于治疗咳喘的复方药物及其制备方法 | |
| CN102106999A (zh) | 一种治疗中风病后吞咽困难的中药复方制剂及其制备方法 | |
| CN101664461B (zh) | 治疗咳嗽的药物组合物 | |
| CN115227759A (zh) | 一种缓解肺炎的吸雾液和吸雾器及其制备方法 | |
| CN104491483A (zh) | 一种改善过敏性疾病的中药组合物、其制备方法及应用 | |
| CN100396279C (zh) | 一种用于治疗心律失常的中药制剂及其制备方法 | |
| CN102357184B (zh) | 一种治疗咳嗽的中药制剂及其制备方法 | |
| CN104524359B (zh) | 一种中药组合物、其制备方法及应用 | |
| CN114259523B (zh) | 一种中药组合物及其在制备治疗咳嗽变异性哮喘的药物中的用途 | |
| CN101024004A (zh) | 一种治疗呼吸道系统疾病的药物组合物及其提取工艺 | |
| CN109745364A (zh) | 一种金荞麦雾化吸入用溶液制剂及其制备方法 | |
| CN101301378B (zh) | 一种止咳润肺的药物 | |
| CN101007058B (zh) | 治疗支气管哮喘、慢性支气管炎和肺气肿症的药物组合物 | |
| CN105560420A (zh) | 一种治疗感染后咳嗽的药物组合物 | |
| CN107243024A (zh) | 一种双金连的药物组合物、一种双金连的雾化吸入用溶液及其制备方法和用途 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| ASS | Succession or assignment of patent right |
Owner name: NORTHWEST UNIVERSITY Free format text: FORMER OWNER: ZHANG YAJUN Effective date: 20130927 |
|
| C10 | Entry into substantive examination | ||
| C41 | Transfer of patent application or patent right or utility model | ||
| SE01 | Entry into force of request for substantive examination | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20130927 Address after: 710069 Shaanxi city of Xi'an province Taibai Road No. 229 Applicant after: NORTHWEST University Address before: 710069 School of life science, Northwestern University, 229 Taibai North Road, Shaanxi, Xi'an Applicant before: Zhang Yajun |
|
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20130619 |